HumanoidHealthcare.Al

The Regulatory Software Brain for Safe Humanoid Care



Andy Squire - Founder | andy@PatientCentricCare.Al

The Problem

A Ticking Liability Time Bomb in Healthcare Robotics





Patient Safety Risk



Catastrophic Manufacturer Liability



Regulation Gap
Unitree R1@5,900
Soon in Homes

Why Now?

Technology is here. Regulation hasn't caught up.

1.6B people aged 65+ by 2050




Aging populations & caregiver shortages



Explosion of humanoid R&D & falling prices



EU Al Act & FDA SaMD frameworks = compliance inevitable



Regulatory development


Medical Robots Market Growth

Medical Robots Market to Reach \$33.8B by 2029

Market: \$18.0B (2024) → \$33.8B (2029)

• CAGR: 16,1%

 Key drivers: Aging population, chronic disease, workforce hortages, Al-enabled robotics




33,8B

Source: MarketsandMarkets, March 2025

Medical Robots Market Segments

Rehabilitation & Hospital Robots Among Fastest Growing



Source: MarketsandMarkets, March 2025

Geographic Opportunities & Trends

Global Growth Led by Asia-Pacific and Emerging Markets

Key geographic insights

- China; Highest CAGR (17.8%) 2024–2029
- India: Strong growth (16.9%)
- Developed markets (US, Germany): Steady growth at lower rates
- Emerging economies: Key opportunities through lower-cost devices and lighter regulatory requirements
- Asia-Pacific & Latin America: Fastest growth in telemedicine and automation-focused applications



Source: MarketsandMarkets, March 2024

Market Barriers & SaMD Opportunity

The Barrier is Not Demand — It's Compliance

Current Challenges



High Upfront Costs (\$0,3-2.5M per system)



Regulatory Hurdles (long, uncertain timelines)



Training & Adoption (limited programs)



Patient/Provider Acceptance (safety concerns)

SaMD Solution Unlocks Market



HumanoidHealthcare SaMD

Explosive adoption in home rehab & eldercare humanoids


Source: MarrketsandMarkets, March 2025

Long-Term Market Outlook

Humanoids: A \$5 Trillion Market by 2050

Key takeways from Morgan Stanley resoarch

- The humanoids market could surpass \$5 trillion by 2050, including sales from supply chains and netwo rks for repair, maintenance and support
- Adoption of humanoids is likely to accelerate in the late 2030s with improved technology as well as greater regulatory and societal support
- Although humanoids are still under development, there could be more than 1 billion by 2050, with 80% used for industrial and commercial purposes





Source: Morgan Stanley, May 14, 2025

Note: This forecast was made BEFORE the new Unitree R1 general purpose Home Humanoid competitive price of \$5,900 - likely to **accelerate adoption**

Our Solution

The SaMD Software Brain:





Product & Technology

Regulation-first architecture, built to scale



- Compliance-ready: ISO 13485, IEC 62304, FDA, EMA
- Patient-centric by design



Patient/Clinician



SaMD Safety Layer



Robot Hardware

Regulatory Advantage

Regulation is not a barrier. It's our moat.

Competitors avoid regulation → exposed

We turn compliance into defensibility



Data-Driven Business Model (DDBM)

Platform orchestrator of the entire humanoid healthcare ecosystem



Partnership Revenue

Joint ventures with OEMs, white-label deployments



Third-Party Licensing

APIs and IP licensing for app developers/insurers



SaMD Licensing

Per-unit licensing for compliance & safety layer



DaaS (Data as a Service)

Predictive algorithms, real-world evidence to hospitals/payers/pharma




HaaS (Hardware as a Service)

Rental/maintenance partnerships with OEMs

High-margin recurring revenues built on regulatory lock-in


Triple Win Ecosystem




We are the orchestrator and central nervous system of humanoid healthcare.

Roadmap & Use of Funds

\$3M Seed builds compliance foundation & validates SaMD







Website PatientCentricCare.Al & Humanoid Healthcare.Al



Traction/Proof

Global interest, early momentum:



Website traffic (last 30 days):

Sweden 34,5 k

USA **27,7 k**

Germany 21,2 k

Singapore 9,2 k

- Research validation: Chalmers, Luleâ, ROBERT® rehabilitation robot
- Regulatory pathway defined





Regulatory Hurdles & Possible Pathway Forward

Team & Advisors





Andy Squire – Founder

35 yrs Pharma Insights, Digital CX, Business & IT 2x cancer survivor & independent Advocate

Advisory Network:



Regulatory Affairs Medical SaMD, MDR



Robotics Engineers HRI Hardware & Software



Clinical Oncology Hospital IT



Ethics & Patient Advocacy & CX

andy@PatientCentricCare.Al 15th Sept, Basel Switzerland